Contact Lens Clinical Trial
Official title:
Safety and Efficacy of Lifitegrast 5% Ophthalmic Solution in Contact Lens Discomfort
The most common reason for contact lens discontinuation is contact lens discomfort. The investigators believe that inflammation plays a role in contact lens discomfort and the use of lifitegrast 5% ophthalmic solution may reduce end of the day contact lens discomfort. This study will enroll 21 contact lens users who will be receiving lifitegrast 5% ophthalmic solution and monitor the contact lens discomfort for a 8 week period while.
Contact lens discontinuation is mostly associated with ocular discomfort. Most patients
identifying dryness as the primary reason for contact lens discontinuation. Patients often
resort to contact lens solutions, lubricating and/or rewetting drops to temporality improve
their contact lens wearing experience. Clinicians often resort to changing contact lens
designs, solutions and wearing modalities to improve comfort.
Contact lens discomfort is believed to be mediated by many factors including inflammation and
very similar in clinical symptoms of dry eye disease and symptoms of dryness.
Lifitegrast 5.0% ophthalmic solution is an FDA approved solution for the management of signs
and symptoms of dryness of dry eye disease. Studies have shown lifitegrast 5% ophthalmic
solution may work by blocking the interaction between ICAM-1 and LFA-1 leading to a decrease
in activation and recruitment of T-cells, an initial step in inflammation.
The safety and efficacy of Xiidra has been studied in four, 12 week clinical trials involving
over 2,100 patients for signs (https://www.xiidra-ecp.com/efficacy-treating-signs) and
symptoms (https://www.xiidra-ecp.com/efficacy-symptom-improvement).
The purpose of this open label, interventional study is to examine the effect of lifitegrast
5% ophthalmic solution in contact lens wearing experience by using the CLDEQ-8.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03682809 -
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
|
Phase 4 | |
| Completed |
NCT05416528 -
Chinese Translation and Validation of the 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8)
|
||
| Completed |
NCT05548491 -
Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)
|
Phase 2 | |
| Completed |
NCT03311204 -
The Effect of Eyelid Margin Debridement on Contact Lens Discomfort
|
N/A | |
| Active, not recruiting |
NCT03652337 -
Meibomian Gland Dysfunction Management
|
N/A | |
| Not yet recruiting |
NCT05801991 -
Neurolens and Contact Lens Discomfort
|
N/A | |
| Completed |
NCT03994406 -
Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
|
Phase 2 | |
| Completed |
NCT02848222 -
Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers
|
N/A |